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Abstract: We recently reported the presence of a novel 32 kDa protein immunoreactive to a 
copper, zinc superoxide dismutase (SOD1) antibody within the spinal cord of patients with 
amyotrophic  lateral  sclerosis  (ALS).  This  unique  protein  species  was  generated  by 
biotinylation  of  spinal  cord  tissue  extracts  to  detect  conformational  changes  of  SOD1 
specific to ALS patients. To further characterize this protein, we enriched the protein by 
column  chromatography  and  determined  its  protein  identity  by  mass  spectrometry.  The 
protein that gave rise to the 32 kDa species upon biotinylation was identified as carbonic 
anhydrase I (CA I). Biotinylation of CA I from ALS spinal cord resulted in the generation of 
a novel epitope recognized by the SOD1 antibody. This epitope could also be generated by 
biotinylation of extracts from cultured cells expressing human CA I. Peptide competition 




assays identified the amino acid sequence in carbonic anhydrase I responsible for binding 
the SOD1 antibody. We conclude that chemical modifications used to identify pathogenic 
protein  conformations  can  lead  to  the  identification  of  unanticipated  proteins  that  may 
participate in disease pathogenesis. 
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1. Introduction 
Chemical modifications of proteins are useful in their applications to enhance and stabilize enzyme 
activities, cross-link different proteins, add tags for tracking and labeling proteins, and probe structural 
differences  in  protein  conformations [1,2].  Protein  modifications  typically  occur  on  amino  acids  
side-chains that are accessible to the chemical reagents. A native protein acquires its conformation 
dependent upon its linear amino acid sequence and the local environment. Multiple conformations 
usually exist for a given protein as a regulatory mechanism for diverse physiological functions [3]. 
This variation in protein conformations also forms the basis for potential differences in the outcome of 
chemical modifications. For example, modifications of the sulfhydryl group of the cysteine residue 
often  result  in  an  increase  in  molecular  mass  of  the  protein  that  can  be  detected  by  immunoblot 
analysis [4].  It  is  also  known  that  chemical  modification  can  result  in  either  loss  or  gain  of 
immunoreactivity to specific antibodies [5,6].  
Mutations  in  the  human  copper,  zinc  superoxide  dismutase  (SOD1)  gene  are  responsible  for 
approximately  2–5%  of  amyotrophic  lateral  sclerosis  (ALS),  an  adult-onset  neurological  disease 
characterized by loss of motor neurons in the spinal cord as well as brainstem and motor cortex [7,8]. 
In an attempt to determine whether there are different SOD1 conformers associated with pathological 
state of ALS, we used biotinylation as a probe to detect potential conformational differences that can 
be observed with the SOD1 antibody by immunoblot and identified a novel 32 kDa immunoreactive 
species [9]. In this study, we identify carbonic anhydrase I (CA I) as the 32 kDa band detected by the 
anti-SOD1 antibody upon biotinylation of specific amino acids within CA I. 
2. Materials and Methods 
2.1. Human Samples 
Human  spinal  cord  autopsy  samples  were  obtained  from  The  Brain  and  Tissue  Bank  for 
Developmental  Disorders  of  the  National  Institute  of  Child  Health  and  Human  Development 
(www.btbank.org, Baltimore, MA, US). 
2.2. Protein Biotinylation  
Cytosolic  proteins  from  post-mortem  tissue  samples  were  prepared  as  described [9].  Protein 
concentrations were measured by the BCA method (Thermo Fisher Scientific, Pierce Protein Research 




proteins were incubated with 10 mM Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific) in PBS buffer, 
pH  7.4  for  25  min  at  25  ° C.  The  reaction  was  stopped  by  adding  free  lysine-HCl  at  a  final 
concentration of 20 mM  for 20 min at  25  ° C. The control  treatment  was  carried out  in  identical 
procedures except omitting Sulfo-NHS-LC-Biotin in the reaction.  
2.3. Western Analysis 
Proteins  were  separated  on  SDS-PAGE  gels  and  transferred  onto  nitrocellulose  membranes. 
Membranes were blocked in TBST, pH 7.4 containing 5% milk, before being incubated with a rabbit 
polyclonal anti-SOD1 antiserum [10] in the same buffer at 4 ° C overnight. Membranes were washed 
with  TBST  and  incubated  with  HRP-conjugated  anti-rabbit  IgG  secondary  antibody  (Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA) for 1 h. Subsequently, membranes were washed 
and visualized via ECL development (GE Healthcare Life Sciences, Piscataway, NJ, USA). 
2.4. Ion Exchange Chromatography 
A total of 200 L of the cytosolic proteins was applied to a prepacked 5 mL anion exchange column 
(HiTrap Q HP, GE Healthcare Life Sciences) using the buffer of 20 mM Triethanolamine (TEA),  
pH 7.8. A total of 32 mL of the same buffer was used to wash the column after the sample loading. 
The flow-through materials were collected in 4 mL fractions (labeled as FT_1 through FT_8). The 
column was then eluted with 20 mM TEA containing 100 mM and 200 mM NaCl, respectively. A total 
of 12 mL elution buffer was used for each salt concentration and eluted proteins were collected in  
4 mL fractions (labeled as 100_1, 2, 3 and 200_1, 2, 3, respectively). Each fraction was reduced to a 
final  volume  of  25  L  using  10  K  NMWL  centrifugal  filter  devices  (Amicon  Ultra-4,  Millipore, 
Billerica,  MA).  An  aliquot  of  each  concentrated  fraction  was  used  for  biotinylation  and  
immunoblot analysis. 
2.5. Purification of the 32 kDa Protein 
The combined FT_2,3,4 fraction from a total of 800 L of cytosolic proteins were separated on 
10% SDS/PAGE and stained with SYPRO (Invitrogen, Carlsbad, CA). Protein bands of interests were 
excised and minced into small pieces. A total of 500 L of the elution buffer (0.25 M Tris-HCl,  
pH  6.8/0.1%  (w/v)  SDS)  was  added  and  samples  vortexed  at  14,000  rpm  for  30  min  at  room 
temperature. The procedure was repeated once to ensure the complete extraction of the protein. The 
supernatant were combined and concentrated via the MWCO-10K centrifugation unit (Amicon Ultra 4, 
Millipore). An aliquot of the eluted protein was biotinylated for the detection of the 32 kDa SOD1-IR. 
2.6. Mass Spectrometry 
The SYPRO-stained 32 kDa protein band was  excised and processed for protein identification. 
Briefly, each gel slice was diced into small pieces (1 ×  1 mm) and placed into an eppendorf tube. The 
gel was treated three times by adding 100 μL of 25 mM NH4HCO3/50% methanol, vortexing for  
10 min, and removing the supernatant, followed by adding 50 μL of 10 mM DTT in 25 mM NH4HCO3 




by adding 50 μL of 55 mM iodoacetamide for incubation in the dark for 45 min at room temperature, 
removing the supernatant and adding 100 μL of 25 mM NH4HCO3/50% methanol and vortexing for  
10 min. Finally, the gel pieces were dehydrated by incubation with 50 μL of 50% acetonitrile (ACN) 
for 10 min and dried completely. Digestion of the protein was performed in 10 μL of 20 ng/μL trypsin 
solution and incubated overnight at 37 ° C before transferring the digest solution into a clean 0.65 mL 
tube. 50 μL of 50% ACN/1% trifluoroacetic acid (TFA) was added to the gel pieces and vortexed for 
30 min. The supernatant was transferred into the same tube. This step was repeated once before drying 
the gel completely. For MALDI-TOF, 3 μL of 50% ACN/1% TFA was added and vortexed for 1 min. 
3 μL of saturated CHCA (a-cyano-4-hydroxycinammic acid) in 50% ACN/1% TFA was added and the 
suspension  was  spotted  on  MALDI  target  and  let  dry.  Acquisition  of  peptide  fingerprinting  and 
MS/MS sequencing data were performed on Applied Biosystems ABI 4700 MALDI-TOF/TOF and 
Bruker Daltomics Ultraflex Ultimate Performance MALDI-TOF & TOF/TOF mass spectrometers. 
Peaks were identified by peptide mass fingerprinting and sequenced by tandem MS/MS. Peptide 
and  amino  acid  sequences  were  compared  to  Mascot  mammalian  protein  database 
(www.matrixscience.com Version 2.2) to confirm identity using a maximum of 1 missed cleavage 
permission and 200 ppm measurement tolerance. 
3. Results 
3.1. Novel Immunoreactivity Recognized by Anti-SOD1 Antibody after Biotinylation 
Cytosolic  proteins  from  spinal  cords  of  ALS  patients  were  treated  with  biotin  followed  by 
immunoblot analysis using the anti-SOD1 antibody (a rabbit polyclonal #354 antiserum against the 
peptide  CYDDLGKGGNEESTK  as  previously  described  by  Pardo  et  al.  [10]).  We  generated  the 
expected  increased  molecular  mass  to  human  SOD1  protein  resulting  from  the  addition  of  biotin 
moieties (Figure 1, lane 1 & lower band of lane 2). In addition, a SOD1-immunoreactive (SOD-IR) 
band of approximately 32 kDa was detected only after biotinylation (Figure 1, indicated by the arrow). 
Two  potential  explanations  can  account  for  this  newly  observed  32  kDa  SOD1-IR  species.  One 
possibility is that biotinylated lysine residues within a different protein give rise to an epitope-like 
domain that is reactive with the anti-SOD1 antibody. Another possibility is that a covalent reaction 
between  SOD1  and  another  protein  occurred  during  the  biotinylation  and  is  responsible  for  the 
generation of the 32 kDa SOD1-IR species. 
In addition, we tested multiple other anti-SOD1 antibodies including a different rabbit polyclonal 
antibody against the same peptide, polyclonal antibodies against different peptides in human SOD1 or 
against the entire protein, as well as monoclonal antibodies against human SOD1, none of which 
resulted in  the same 32 kDa-IR band as  seen with  the #354 antiserum  (data not  shown). For the 
remainder  of  the  experiments  in  this  study,  only  #354  antiserum  is  used  for  the  detection  of  the  
32 kDa-IR band. 




Figure  1. Novel immunoreactivity of the SOD1 antibody to a protein of 32 kDa after 
biotinylation. Spinal cord cytosolic proteins from an ALS subject in the absence (-) and 
presence (+) of biotin were analyzed by immunoblot analysis using the SOD1 antibody. 
Protein molecular weight markers are noted on the left. A protein band of 32 kDa became 
detectable only after biotinylation (indicated by the arrow). 
 
3.2. Purification and Identification of the Protein That Gives Rise to the 32 kDa-IR 
In  order  to  characterize  the  protein  that  generates  the  observed  32  kDa-IR,  we  purified  the  
32 kDa-IR signal by column chromatography. We found that anion exchange chromatography of the 
soluble tissue extract provided enrichment of a protein that produced the 32 kDa-IR upon biotinylation. 
The protein that generated the 32 kDa-IR was collected within column flow-through fractions FT_2 to 
FT_4 while all native molecular mass SOD1 was concentrated in the salt-eluted fractions (Figure 2A). 
This result indicates that the 32 kDa-IR signal was not generated from covalent linkage between an 
SOD1 molecule and another protein during the biotinylation reaction. The proteins in the combined 
fractions (FT_2 to FT_4, labeled as FT2,3,4) were separated and visualized by anti-SOD1 immunoblot 
as a single, broad 32 kDa band but via SYPRO staining were resolved as a protein doublet (Figure 2B, 
solid rectangular box). In order to determine which band in the doublet gave rise to the 32 kDa-IR 
signal, both bands were excised individually from the gel, eluted, biotinylated, and immunolabeled 
with  #354  antiserum.  We  determined  that  the  upper  gel  (labeled  E1)  is  the  protein  that  upon 
biotinylation gave rise to the immunoreactivity to #354 antiserum (Figure 2C). This same band was 
further processed for peptide fingerprinting and amino acid sequencing via MALDI-TOF/TOF mass 
spectrometry as described in Section 2. Amino acid sequence information from 12 peptides generated 
by tryptic digestion demonstrated that carbonic anhydrase I (CA I) is the protein in gel band E1, with 









Figure 2. Purification of the protein species that gives rise to the 32 kDa-IR signal after 
biotinylation. All immunoblot analysis were performed with proteins either treated with  
(+)  or  without  (-)  biotin  and  detected  by  #354  antiserum.  (A)  The  32  kDa  protein  is 
partially purified in the flow-through (FT) fractions via anion exchange chromatography as 
described in Materials and Methods. A total of 200 L of the cytosolic proteins from the 
SALS spinal cord were used. (B) Fractions from FT_2 to FT_4 were combined as FT2,3,4 
and analyzed by both immunoblot analysis (left) and SYPRO staining (right) to visualize 
the proteins. Two protein bands were seen at the 32 kDa position by SYPRO (indicated by 
the solid rectangular box). The upper (E1) and lower (E2) band of the doublet, together 
with a strong protein band above the 45 kDa (E3), and a comparable size gel piece lacking 
any apparent protein bands by SYPRO, were excised, proteins eluted and treated by biotin, 
and analyzed via Western (C). The 32 kDa-IR signal is indicated by the arrow in (C).  








Figure 3. Identification of the purified protein as CA I. The E1 gel band from Figure 2 was 
digested  with  trypsin  and  subjected  to  amino  acid  sequencing  by  mass  spectrometry. 
Details from the analyses used to identify band E1 as carbonic anhydrase I (CA I) are 
summarized.  The  protein  score  refers  to  a  MASCOT  search  against  the  mammalian  
Swiss-Prot dataset with up to one missed tryptic cleavage site. A protein score greater than 
68 is significant (p < 0.05). The matched peptide sequences, representing 68% of the CA I 
protein sequence, are shown.  
 
3.3. Human CA I Is Necessary and Sufficient to Give Rise to the 32 kDa-IR Species upon Biotinyation 
To further determine whether human CA I is responsible for generating the 32 kDa-IR species upon 
biotinylation, we tested the ability of human CA I to generate the 32 kDa-IR in cultured cells. HEK 
cells  do  not  express  detectable  levels  of  endogenous  CA  I,  but  after  transfection  with  a  plasmid 
containing human CA I we detected a 30 kDa immunoreactive band that also increased in molecular 
mass  to  32  kDa  after  biotinylation  by  an  anti-CA  I  antibody  (Figure  4,  right  panel).  In  contrast, 
transfection  with  a  control  plasmid  containing  prolactin  (ProL)  failed  to  generate  any  anti-CA  I 
immunoreactive bands (Figure 4, right panel). Furthermore, only HEK cells expressing human CA I, 
but  not  ProL, exhibited the 32 kDa-IR band upon biotinylation,  in  addition  to  endogenous  native  
20 kDa hSOD1 when probed by the #354 antiserum (Figure 4, left panel)  
We  also  investigated  whether  endogenous  mouse  CA  I  was  capable  of  generating  the  same  
32 kDa-IR species upon biotinylation, as there is an overall 78% homology between human and mouse 




mice  were  examined  and  the  32  kDa-IR  signal  was  not  detected  by  the  #354  antiserum  
(Supplementary data). 
The above results demonstrate that only human CA I is both necessary and sufficient to generate the 
32 kDa-IR species upon biotinylation.  
Figure 4. Human CA I is necessary and sufficient for 32 kDa-IR species to #354 antiserum 
upon biotinylation. Immunoblot analysis of proteins from HEK cells transiently transfected 
with  human  CA  I  (hCA  I)  or  prolactin  (ProL)  treated  without  (-)  or  with  (+)  biotin. 
Identical samples were used for two blots which were probed with #354 antiserum (left 
panel) and anti-CA I (right panel) antibodies, respectively. 
 
3.4. Biotinylation of an Epitope-Like Sequence in Human CA I Resulted in the Novel Immunoreactivity 
To further understand the mechanism by which CA I obtained immunoreactivity to #354 antiserum 
upon  biotinylation,  we  performed  peptide  competition  experiments  using  three  different  peptides 
(Figure 5A). Peptide 1 is a portion of the sequence used to generate the anti-SOD1 antibody. Peptide 2 
is a sequence identified within CA I that exhibits 50% sequence identity to peptide 1 as determined by 
SIM  alignment  tool [11],  and  peptide  3  is  an  unrelated  sequence  used  as  a  negative  control.  The 
identical amino acids between peptide 1 & 2 are indicated by bold letters, including two lysine (K) 
residues  that  can  be  biotinylated.  As  expected,  peptide  1  competed  and  eliminated  the 
immunoreactivity  for  both  the  native  20  kDa  hSOD1  and  the  32  kDa-IR  species  (Figure  5B,  
lanes 3–8), as it occupied the epitope-recognition site in the antibody. In contrast, peptide 2 did not 
compete either immunoreactive species, while biotinylated peptide 2 competed only the 32 kDa-IR 
species (Figure 5B, lanes 9–16, 23–28). This data demonstrated that peptide 2 does not interact with 
the epitope-recognition site in the antibody, but upon biotinylation it could occupy the site. Peptide 3 
that lacks homology to either peptide 1 or 2 failed to compete #354 antiserum recognition on either the 
two  immunoreactive  signals  (Figure  5B,  lanes  17–18).  Together,  these  data  further  indicate  that 
biotinylated amino acids within peptide 2 of CA I give rise to the 32 kDa-IR.  
 
 




Figure 5. A biotinylated epitope-like sequence in human CA I is responsible for the novel 
immunoreactivity to #354 antiserum. (A) Sequences and alignment of the three peptides 
used in the peptide competition experiments. Identical amino acids were indicated in bold. 
(B) Peptide competition experiments were carried out by immunoblot analysis of cytosolic 
proteins from an ALS spinal cord in the absence (-) or presence (+) of biotin using #354 
antiserum. Multiple blots with identical sample preparations were used for incubations with 
the  antibody:  (i)  alone;  (ii)  pre-absorbed  with  different  amounts  of  peptides;  or  iii)  
pre-absorbed with biotinylated peptides. The labels for the table above the blot: “g”: the 
amount of the peptide used; “peptide”: either no peptide (as “none”) or which peptide (as 
“1”,  “2”,  or  “3”)  was  used  in  pre-absorption  with  the  antibody;  “biotin”:  whether  the 
peptide was biotinylated or not (as “y” or “n“, respectively); “ratio”: molar ratio of the 
peptide to biotin.  
 
4. Conclusions 
Although it is known that chemical modifications of amino acid side-chains in the protein can alter 
immunoreactivity to antibodies, most involve either an increase or loss of affinity to the antibodies 
against that particular protein [5] or a closely related protein [6]. Protein biotinylation generating novel 
immunoreactivity to an antibody to an unrelated protein is uncommon. In this report, we elucidated the 
mechanism by which such phenomenon can occur by detecting biotinylated proteins using immunoblot 
analysis with the SOD1 antibody #354. 
The  results  of  this  study  demonstrate  that  protein  modifications  can  potentially  generate  novel 
conformational features that may be detected by antibodies to disparate proteins. Our specific example 
identifies a peptide sequence in human CA I that upon biotinylation, is sufficient and necessary to be 
recognized by a polyclonal anti-SOD1 antibody generated against a SOD1-specific peptide sequence 
(#354 polyclonal antiserum). This certainly is unexpected and rather an uncommon event. In fact, the 
32 kDa species was suggested to be an SOD1-dimer which contained SOD1 protein sequences when 




human CA I, a protein unrelated to SOD1, is responsible for generating a biotinylated species that is 
recognized by the SOD1 antibody.  
This  study  is  important  in  the  following  two  aspects.  First,  we  have  identified  a  molecular 
mechanism underlying newly gained epitope recognition to an antibody of an unrelated protein due to 
chemical modifications of amino acid side-chains. The molecular basis is the peptide sequence in 
human CA I which shares 50% homology to the epitope sequence in human SOD1 that was used to 
generate the #354 polyclonal antiserum. This peptide sequence homology is not sufficient to result in a 
cross-reaction of the CA I protein with the anti-SOD1 antibody by traditional immunoblot analysis. In 
addition to the amino acid sequence homology, the potential electrical charges that are imparted by 
lysine and glutamic acid residues can serve as a barrier to the antibody recognition if a hydrophobic 
interaction  is  involved.  However,  biotinylation  of  the  CA  I  protein  within  this  peptide  sequence 
generates  an  epitope-like  structure  within  CA  I  that  becomes  immunoreactive  to  #354  antiserum. 
Therefore, features other than high homology within the amino acid sequence must be considered 
when evaluating the basis of peptide antibody recognition, especially if chemical modifications are 
performed to the protein. What are the potential explanations for #354 polyclonal antiserum to react to 
both biotinylated CA I as well as the SOD1 epitope? The answer is either the two epitope recognition 
sites  are  in  the  same  linear  sequence  of  amino  acids  or  that  biotinylation  of  CA  I  generates  a 
conformational epitope that is now recognized by the anti-SOD1 antibody. We know that biotinylated 
CA  I  peptide  cannot  block  the  SOD1-recognition  site  while  the  SOD1  peptide  can  block  both 
recognition sites. Further studies are required to address this issue. However our results do suggest that 
careful characterizations of the nature of antibody and protein recognition is warranted in experimental 
investigations,  especially  those  involving  alterations  of  protein  side-chain  structures  such  as  the 
biotinylation approach used in our studies [9].  
Protein identification via mass spectrometry determined that CA I is the molecule that acquires 
immunoreactivity to anti-SOD1 antibody upon protein biotinylation. Recent studies have demonstrated 
that antibodies against the P2X4 subunit of the ATP receptor recognize misfolded mutant G93A SOD1 
in a transgenic mouse model of ALS [12], indicating that protein misfolding may also induce antibody 
cross reactivity. 
Our study has identified a protein, not previously implicated in ALS, in an unbiased albeit limited 
way by use of a specific SOD1 antibody. CA I is a cytosolic protein known to function in carbon 
dioxide transport within cells and at the level of mitochondria [13], and its carbonic anhydrase activity 
contributes  to  maintaining  cellular  pH  homeostasis [14].  Inhibition  of  CA  I  can  reduce  muscle 
contraction and calcium storage capacity [15], and increased plasma levels of carbonic anhydrase III 
has been detected in patients with neuromuscular disorders [16]. CA I is an abundant protein in blood 
and can also be detected in cerebrospinal fluid (CSF) (Liu et al., unpublished result). Initial screenings 
of CA I from either blood or CSF samples from normal and ALS patients did not reveal observable 
differences between the two populations (Liu et al. unpublished results). However, characterization of 
neuronal CA I has not been reported and awaits future studies. While the contribution of CA I to ALS 
pathology and disease pathogenesis  remains unclear, further exploration of CA I in motor neuron 
disease is warranted and may lead to new therapeutic opportunities for ALS.  
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Supplementary data 
Figure  S1.  The  32  kDa-IR  species  is  not  detected  in  the  spinal  cord  of  SOD1-linked 




 containing the human wild-type and G85R mutant SOD1s, respectively) were 
treated with (+) or without (-) biotin and probed with the #354 anti-SOD1 antiserum via 
immunoanalysis as described in Materials & Methods. A positive control from a human 
sample for the 32 kDa-IR species was included (Human). mSOD1: endogenous mouse 
SOD1.  Molecular  weight  markers  are  indicated  on  the  left.  Biotinylated  mSOD1  and 
hSOD1 are both up-shifted in the presence of biotin.  
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